Month: January 2021
ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares
Geneva, Switzerland and Boston, MA – Thursday 28 January, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss…
JPM Presentation Jan 14, 2021
ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
– European Medicines Agency Validates Yselty MAA for Uterine Fibroids; US NDA Planned for 1H 2021 – Phase 3 EDELWEISS…
ObsEva SA to Participate in JP Morgan Virtual Healthcare Conference January 11 – 14, 2021
Geneva, Switzerland and Boston, MA – January 7, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company…
ObsEva appoints David Renas as Chief Financial Officer
Geneva, Switzerland and Boston, MA – January 4, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…